SCHEMBL16670340

SCHEMBL16670340

CCC(NC(=O)O)C(=O)Cc1cccc(F)c1C(=O)Nc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 4/20 0.43
ITGA4 P13612 4/20 0.43
TRPA1 O75762 3/20 0.42
GAA P10253 2/20 0.42
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
TYK2 P29597 1/20 0.41
HTT P42858 1/20 0.41
NOD2 Q9HC29 1/20 0.41
MEN1 O00255 5/20 0.41
KMT2A Q03164 5/20 0.41
RAB9A P51151 4/20 0.40
LMNA P02545 1/20 0.39
NPC1 O15118 2/20 0.39
KDM4E B2RXH2 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
BCAT2 O15382 1/20 0.39
MAPT P10636 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16677545 0.87 CTSK (0.48) ITGB1ITGA4GAARAB9AMAPT
SCHEMBL16583355 0.81 MEN1 (0.44) ITGB1ITGA4TRPA1GAAJAK2
SCHEMBL16670341 0.80 MEN1 (0.44) ITGB1ITGA4TRPA1GAAJAK2
SCHEMBL16677246 0.77 F2R (0.49) TRPA1GAAJAK2JAK1TYK2
SCHEMBL935527 0.74 ITGB1 (0.46) ITGB1ITGA4GAATYK2MEN1
SCHEMBL19576319 0.74 GAA (0.43) ITGB1ITGA4TRPA1GAAJAK2
SCHEMBL30739749 0.72 JAK2 (0.71) GAAJAK2JAK1TYK2HTT
SCHEMBL21174715 0.72 ITGB1 (0.47) ITGB1ITGA4JAK2JAK1TYK2
SCHEMBL21174718 0.72 ITGB1 (0.47) ITGB1ITGA4JAK2JAK1TYK2
SCHEMBL16583943 0.72 GAA (0.59) ITGB1ITGA4TRPA1GAAJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160244452-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS INC (US) 2016-08-25 US claimed
WO-2015061204-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. (US) 2015-04-30 WO claimed
US-20160244452-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS INC (US) 2016-08-25 US disclosed
WO-2015061204-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF INFINITY PHARMACEUTICALS, INC. (US) 2015-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244452-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF PIK3CA, PIK3CD, PIK3CB ITGB1 3395/4885ITGA4 3977/4885TRPA1 4020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.